Tag

Esc 2026

All articles tagged with #esc 2026

health1 month ago•3 min saved

Xylitol Linked to 57% Higher Heart Risk in Large Observational Study

A large observational study presented at the European Society of Cardiology Congress 2026 found that high blood levels of xylitol, a common sweetener, are associated with a significantly increased risk of major adverse cardiovascular events. The analysis of 17,710 participants from Canada and Europe showed a 57% higher risk in one cohort and an 18% higher risk in another, suggesting a dose-dependent relationship. While the study does not prove causation, experts warn that xylitol may not be a safe substitute for sugar, particularly for those with existing heart conditions.

via Medical News Today|

#artificial-sweeteners #cardiovascular-health #epidemiology

health1 month ago•0 min saved

Statins Linked to 15% Lower Dementia Risk in Large Danish Study

A 15-year observational study of over 132,000 Danish patients with type 2 diabetes suggests that starting statins early in life reduces the risk of developing dementia by 15%, while later initiation lowers risk by 10%. Presented at the European Society of Cardiology (ESC) Congress 2026, the findings indicate that managing low-density lipoprotein (LDL) cholesterol may protect brain health by preventing vascular damage. While experts emphasize that statins are widely available and inexpensive, they caution that observational data cannot prove causation. Concurrently, the STAREE trial reported that atorvastatin reduces major cardiovascular events by 30% in adults over 70, though it did not show a significant reduction in dementia incidence. These results reinforce the link between cardiovascular health and brain function, suggesting that early cholesterol management could be a key strategy in preventing or delaying dementia, which is forecast to affect 153 million people globally by 2050.

via The Guardian|

#cardiovascular-health #dementia #esc-2026

health-and-medicine1 month ago•5 min saved

STAREE Trial: Atorvastatin Reduces Cardiovascular Events in Adults Over 70, But Not Disability-Free Survival

The STAREE trial demonstrates that atorvastatin reduces major cardiovascular events by 30% in adults aged 70 and older without prior heart disease, though it does not improve disability-free survival or reduce dementia risk.

via Medscape|

#cardiology #esc-2026 #geriatrics